SCHEMBL30765837

SCHEMBL30765837

CC(C(=O)O)n1c(-c2ccccc2F)ncc(N[C@H](C)c2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.35
DDR2 Q16832 1/20 0.35
MMP12 P39900 2/20 0.35
MMP13 P45452 2/20 0.35
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
GBA1 P04062 1/20 0.34
KMT2A Q03164 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
ASPH Q12797 1/20 0.33
RIOX2 Q8IUF8 1/20 0.33
KDM8 Q8N371 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPY5R Q15761 1/20 0.33
USP5 P45974 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
MAPK14 Q16539 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765669 1.00 KIT (0.35) KITDDR2MMP12MMP13KDM4E
SCHEMBL30765760 0.93 CYP1A2 (0.36) KITDDR2KDM4EMEN1KMT2A
SCHEMBL30766151 0.87 ELANE (0.37) KITDDR2HSP90AA1HSP90AB1CYP2C9
SCHEMBL30765981 0.82 LMNA (0.37) KDM4EMEN1KMT2AASPHRIOX2
SCHEMBL31558470 0.82 LMNA (0.37) KDM4EMEN1KMT2AASPHRIOX2
SCHEMBL30765454 0.80 ELANE (0.37) KITDDR2CYP1A2CYP2C9CYP2C19
SCHEMBL30765745 0.79 ELANE (0.37) MMP12MMP13HSP90AA1HSP90AB1CYP2C9
SCHEMBL31558409 0.78 POLB (0.36) MMP12MMP13KDM4EHSP90AA1HSP90AB1
SCHEMBL30765602 0.77 GPR139 (0.37) KDM4EMEN1GBA1KMT2AHSP90AA1
SCHEMBL31558435 0.77 ELANE (0.45) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed